Linezolid-induced haematological toxicity

Area of Science:

• Infectious Diseases
• Hematology
• Pharmacology

Background:

• Linezolid is a crucial antibiotic for treating Gram-positive bacterial infections.
• Hematological toxicity, including neutropenia and thrombocytopenia, is a known side effect of linezolid.
• The influence of renal impairment and potential protective agents like pyridoxine on linezolid toxicity requires further investigation.

Purpose of the Study:

• To determine the incidence of linezolid-induced hematological toxicity.
• To assess the impact of renal clearance on the occurrence of this toxicity.
• To evaluate the potential preventive effect of pyridoxine against linezolid-induced hematological toxicity.

Main Methods:

• A retrospective observational study included patients treated with linezolid over six months.
• Hematological toxicity was defined by specific percentage decreases in hemoglobin, platelets, and neutrophils.
• Statistical analyses (Chi-Square, U Mann-Whitney) compared toxicity incidence based on renal failure status and pyridoxine use.

Main Results:

• 42% of patients experienced hematological toxicity, most commonly affecting platelets and neutrophils.
• Toxicity incidence was similar in patients with and without renal failure (42% vs. 42%, p=0.970).
• Patients with renal failure exhibited a significantly greater reduction in platelet count (p=0.0185).

Conclusions:

• Linezolid commonly causes hematological toxicity, primarily impacting platelet and neutrophil counts.
• Renal failure did not significantly increase the overall incidence of linezolid-induced hematological toxicity.
• Pyridoxine did not show a significant preventive effect, but renal impairment worsened platelet reduction.